England’s cost watchdogs are changing their tune on Alexion’s rare bone disorder drug Strensiq--but not quite as much as the drugmaker would like.

With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…

Sarepta Therapeutics has been waiting, hoping and lobbying for approval of its Duchenne muscular dystophy drug eteplirsen for years. And now--despite intra-…

Mylan saw EpiPen pricing trouble coming months ago. So the company stepped up lobbying for EpiPen's move onto an official list of preventive meds that…

The FDA has banned all of the products made by an Indian drugmaker as it investigates an outbreak of dozens of hospital infections. 

Pfizer’s stop-smoking drug Chantix may be one step closer to escaping the FDA’s black box. An agency advisory panel narrowly voted in favor of removing the FDA…

Not atypically, the FDA questioned Pfizer’s Chantix data up for discussion at a meeting Wednesday. But agency reviewers also raised an unusual flag: Pfizer…

Congress is starting to get some answers on EpiPen pricing. And though, so far, Mylan’s not offering much beyond what’s readily available via Google search,…